F/m Emerald Life Sciences Innovation ETF
Filed by RBB Fund, Inc.. What this fund reported holding in its latest quarterly NPORT-P. Positions are ordered by share of the fund rather than by size, because that is what separates a conviction from a rounding error.
What it holds
Largest share of the fund first.
| Company | % of fund | Value |
|---|---|---|
| COGTCogent Biosciences Inc | 6.48% | $8.2M |
| GHGuardant Health Inc | 3.81% | $4.8M |
| CYTKCytokinetics Inc | 3.50% | $4.4M |
| UTHRUnited Therapeutics Corp | 3.27% | $4.1M |
| AXSMAxsome Therapeutics Inc | 3.05% | $3.9M |
| NKTRNektar Therapeutics | 2.97% | $3.8M |
| ICUIICU Medical Inc | 2.77% | $3.5M |
| TWSTTwist Bioscience Corp | 2.03% | $2.6M |
| NEONeogenomics Inc | 1.21% | $1.5M |
| GMEDGlobus Medical Inc | 1.08% | $1.4M |
| PRAXPraxis Precision Medicines Inc | 0.98% | $1.2M |
| INSMInsmed Inc | 0.60% | $761.1K |
Source: NPORT-P filings, via EDGAR. Positions arrive by CUSIP, and only a CUSIP verified against a ticker is kept — so this is what we could match, not everything the fund holds, and the matched value is therefore below the fund's own size. A balance is shares where the filing says `NS` and a principal amount where it says `PA`, which is why it is not labelled shares in both cases.
Follow F/m Emerald Life Sciences Innovation ETF by email
F/m Emerald Life Sciences Innovation ETF's new holdings reports, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.